Contact
  • Antineo
    • Retour
    • green modern bacteriological laboratory banner 11Antineo
    • Track-Record
    • Mission and Vision
    • Our team
    • Our scientific commitee
    • Animal use at Antineo
  • Preclinical services
    • Retour
    • endpoint assays, drug efficacy studiesPreclinical services
    • In vitro preclinical services
      • Retour
      • In vitro Endpoint studies
      • In vitro continuous-monitoring studies
      • Sample Characterisation
    • Ex vivo preclinical services
    • In vivo preclinical services
    • Preclinical development of immunotherapies
  • Tumour models
    • Retour
    • sans titre 67Tumour models
    • Syngeneic tumour models
      • Retour
      • Liquid tumours in Syngeneic models
      • Solid tumours in Syngeneic models
    • Cell-Derived Xenografts
    • Patient-Derived Xenograft
    • Original preclinical resistant tumour models
  • Our Strengths
    • Retour
    • copie de green modern bacteriological laboratory bannerOur Strengths
    • Facilities & ressources
    • Equipment
    • networks and partnerships
  • News & Events
    • Retour
    • News & Events
    • News
    • Press Release
    • Posters
    • Events
    • Upcoming Events
    • Resources
    • Presentation Corporate 2025
  • Publications
  • Application notes

Posters

Home > Posters

Poster #1 – Development of Luciferase cell lines allows tumor monitoring with the Ivis Imager®
Poster #2 – Characterization of acquired resistant models to therapies targeting the PD-1 / PD-L1 axis demonstrates model-dependant mechanisms
Poster #3 – DIACCURATE : DIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER+ HER2 – metastatic breast cancer
Poster #4 – BRENUS PHARMA : 1179 efficacity study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC38 syngeneic colon cancer tumor model
Tumour models
  • Cell-Derived Xenografts
  • Syngeneic tumour models
  • Original preclinical resistant tumour models
  • Patient-Derived Xenograft
Preclinical services
  • In vitro preclinical services
  • ex vivo preclinical services
  • in vivo preclinical services
  • Preclinical development of immunotherapies
Our strengths
  • Facilities & ressources
  • Equipment
  • networks and partnerships
Contact & News
  • Contact us
  • News & Events
  • Publication
  • Your career at Antineo !
  • Legals
We use cookies to guarantee you the best experience on our websiteOkNoPrivacy policy
 Revoke consent